Pharmacogenomics in Psychiatry: CYP450 Enzymes, Gene-Drug Interactions, Clinical Utility, and Limitations

Psychiatric pharmacotherapy remains heavily characterized by trial-and-error prescribing. Approximately 30–50% of patients with major depressive disorder (MDD) do not respond adequately to their first antidepressant, a finding underscored by the landmark STAR*D trial, in which only 37% of patients achieved remission with initial citalopram monotherapy. Among patients with schizophrenia, the CATIE trial revealed that 74% discontinued their first assigned antipsychotic within 18 months, often due to intolerable side effects or inadequate efficacy. These sobering statistics have fueled interest in pharmacogenomics (PGx)—the study of how inherited genetic variation influences drug response—as a tool to move psychiatric prescribing from population-level algorithms toward individualized treatment selection.

Pharmacogenomic testing in psychiatry primarily interrogates genes encoding drug-metabolizing enzymes, particularly the cytochrome P450 (CYP450) superfamily, but also extends to pharmacodynamic targets such as serotonin transporters (SLC6A4), serotonin receptors (HTR2A, HTR2C), dopamine receptors (DRD2), and the blood-brain barrier efflux transporter ABCB1 (P-glycoprotein). This article provides a detailed clinical review of the mechanisms, evidence base, clinical utility, and significant limitations of pharmacogenomics in psychiatric practice.

The cytochrome P450 enzyme system is a superfamily of heme-containing monooxygenases primarily expressed in hepatocytes, responsible for the Phase I oxidative metabolism of approximately 70–80% of clinically used medications. In psychiatry, the most clinically relevant isoenzymes are CYP2D6, CYP2C19, CYP3A4, CYP1A2, and CYP2B6.

CYP2D6

CYP2D6 is the most extensively studied pharmacogene in psychiatry. It metabolizes approximately 25% of all prescribed drugs, including most tricyclic antidepressants (TCAs), several SSRIs (fluoxetine, paroxetine, fluvoxamine), SNRIs (venlafaxine), atypical antipsychotics (aripiprazole, risperidone, haloperidol, iloperidone), and opioid analgesics (codeine, tramadol). The CYP2D6 gene on chromosome 22q13.2 is highly polymorphic, with over 130 defined allelic variants cataloged by the Pharmacogene Variation Consortium (PharmVar).

Individuals are classified into metabolizer phenotypes based on their diplotype activity score:

• Poor metabolizers (PMs): Carry two nonfunctional alleles (e.g., *4/*4, *5/*5). Prevalence: ~5–10% of European-ancestry populations, ~1–2% of East Asian populations.
• Intermediate metabolizers (IMs): Carry one reduced-function and one nonfunctional allele. Prevalence: ~10–15% depending on ancestry.
• Normal metabolizers (NMs): Previously termed "extensive metabolizers." Carry two functional alleles. Prevalence: ~60–70%.
• Ultrarapid metabolizers (UMs): Carry gene duplications or multiplications (e.g., *1xN, *2xN) resulting in elevated enzyme activity. Prevalence: ~1–2% of Northern Europeans but up to 29% of Ethiopian and 10% of Southern European populations.

The clinical implications are direct: CYP2D6 PMs prescribed standard-dose nortriptyline may accumulate plasma concentrations 2–4 times higher than NMs, increasing risk of QTc prolongation, anticholinergic toxicity, and serotonin syndrome. Conversely, CYP2D6 UMs prescribed codeine may generate dangerously high morphine levels through accelerated O-demethylation—a pharmacogenomic interaction that has resulted in documented fatalities, particularly in pediatric populations.

CYP2C19

CYP2C19, located on chromosome 10q23.33, is the primary metabolic pathway for citalopram, escitalopram, sertraline (partially), clobazam, and several proton pump inhibitors. The most clinically actionable variants are *2 (c.681G>A, a splice-site variant creating a premature stop codon) and *17 (a promoter variant associated with increased transcription and ultrarapid metabolism). CYP2C19 PM prevalence is approximately 2–5% in European-ancestry populations and 12–23% in East and Southeast Asian populations, reflecting significant ethnoracial variation that has direct dosing implications.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides Level A (strongest) evidence-based guidelines for CYP2C19-guided dosing of citalopram and escitalopram: PMs should receive a 50% dose reduction of citalopram (maximum 20 mg/day), and UMs may require an alternative agent due to expected subtherapeutic drug levels.

CYP3A4, CYP1A2, and CYP2B6

CYP3A4 metabolizes quetiapine, lurasidone, buspirone, and many benzodiazepines (alprazolam, midazolam, triazolam). While CYP3A4 is less polymorphic than CYP2D6, it is highly susceptible to environmental drug-drug interactions—potent inhibitors (ketoconazole, ritonavir, grapefruit juice) and inducers (carbamazepine, rifampin, St. John's wort) can alter substrate drug levels by 5- to 10-fold, often exceeding the magnitude of genetic variation.

CYP1A2 metabolizes clozapine, olanzapine, duloxetine, and theophylline. Smoking (via polycyclic aromatic hydrocarbon induction, not nicotine) robustly induces CYP1A2 activity, requiring dose adjustments of up to 50–100% for clozapine in smokers versus nonsmokers. Genetic variation (e.g., *1F) contributes additional interindividual variability.

CYP2B6 is the primary metabolizer of bupropion and methadone. The *6 allele (reduced function) has a frequency of ~25% in African-ancestry populations and is associated with higher hydroxybupropion-to-bupropion ratios, though clinical dosing guidelines for CYP2B6 remain less mature than for CYP2D6 and CYP2C19.

While CYP450 pharmacokinetics dominates current commercial PGx panels, pharmacodynamic genes—those encoding the molecular targets of psychiatric medications—represent a complementary and mechanistically distinct domain of pharmacogenomic research.

SLC6A4 (Serotonin Transporter Gene)

The serotonin transporter gene SLC6A4 contains a well-studied insertion/deletion polymorphism in its promoter region, known as 5-HTTLPR. The short (S) allele is associated with reduced transcriptional efficiency and lower serotonin transporter expression. Early studies, including Serretti and colleagues' meta-analyses, suggested the L/L genotype was associated with better SSRI response, with an odds ratio of ~1.5 for remission. However, subsequent larger studies have yielded inconsistent results, and the GENDEP study found only modest effects that were SSRI-specific (escitalopram but not nortriptyline), suggesting gene-drug specificity rather than a general pharmacogenomic effect.

HTR2A (Serotonin 2A Receptor)

Variants in HTR2A, particularly rs7997012 (an intronic SNP), were associated with citalopram response in the STAR*D pharmacogenomic substudy, with the A/A genotype showing an approximately 18% absolute improvement in response rate compared to G/G carriers. This receptor is the primary pharmacological target of many atypical antipsychotics and psychedelics, making it a pharmacodynamically plausible candidate. However, replication has been inconsistent, and HTR2A variants are not yet included in CPIC guidelines with actionable recommendations.

HLA-A and HLA-B (Immunopharmacogenomics)

Perhaps the most clinically actionable pharmacodynamic PGx test in psychiatry involves HLA-B*15:02 screening before prescribing carbamazepine. Carriers of this allele, predominantly found in Southeast Asian populations (prevalence ~8–15% in Han Chinese, Thai, and Malay populations versus <1% in European-ancestry populations), have a dramatically elevated risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), with an odds ratio exceeding 100. The FDA mandates HLA-B*15:02 testing before carbamazepine initiation in at-risk populations. Similarly, HLA-A*31:01 testing is recommended in some guidelines for broader populations, as this allele (prevalence ~2–5% in European and Japanese populations) is associated with carbamazepine-induced hypersensitivity reactions including drug reaction with eosinophilia and systemic symptoms (DRESS).

COMT and Other Candidate Genes

Catechol-O-methyltransferase (COMT) Val158Met (rs4680) affects prefrontal dopamine catabolism and has been studied in relation to antipsychotic response and cognitive function in schizophrenia. The Met/Met genotype (low-activity) is associated with higher prefrontal dopamine availability. While biologically plausible, the clinical effect sizes for treatment prediction are small and inconsistent, and this variant is not included in current clinical PGx guidelines.

The clinical utility of pharmacogenomic testing in psychiatry has been evaluated in multiple randomized controlled trials (RCTs), with the strongest evidence base existing for depression treatment.

The GUIDED Trial (Genomics Used to Improve DEpression Decisions)

Published in 2019 by Greden et al. in the Journal of Psychiatric Research, this was the largest RCT of combinatorial PGx testing (using the GeneSight panel) in treatment-resistant depression. The trial enrolled 1,167 patients with inadequate response to at least one prior antidepressant. Patients were randomized to PGx-guided care versus treatment as usual (TAU). The primary outcome (HAM-D17 response rate at week 8) showed a non-significant trend (26.0% vs. 19.9%, p = 0.107 in the modified intention-to-treat analysis). However, in a post hoc analysis limited to patients whose baseline medication was flagged as having significant gene-drug interactions (the "red bin" category), switching to a congruent medication yielded a remission rate improvement of approximately 50% relative to TAU.

Critics note the open-label design on the clinician side, the limited clinical significance of the primary outcome difference, and the reliance on post hoc subgroup analyses. Nonetheless, the GUIDED trial remains the most cited prospective study in psychiatric PGx.

The IMPACT Study

Published by Bousman et al. (2023) in JAMA Network Open, this Australian RCT randomized 276 patients with MDD or generalized anxiety disorder to PGx-guided versus unguided prescribing. At 12 weeks, the PGx-guided group showed a significantly higher remission rate of 42% versus 24% (p = 0.008), with a number needed to treat (NNT) of approximately 6. This was one of the first RCTs to demonstrate a statistically significant difference on the primary endpoint.

Meta-Analytic Evidence

A 2021 systematic review and meta-analysis by Bousman et al. in Pharmacogenomics Journal pooled data from 10 RCTs (total N > 5,000 patients) and found that PGx-guided prescribing was associated with a 1.7-fold increase in the odds of remission (OR = 1.71, 95% CI: 1.17–2.48) and a 1.4-fold increase in odds of response (OR = 1.40, 95% CI: 1.10–1.77) compared to unguided care. The heterogeneity across studies was moderate (I² ~45–60%), reflecting differences in PGx panels, clinical populations, and outcome definitions.

However, another meta-analysis by the EGAPP Working Group (Evaluation of Genomic Applications in Practice and Prevention) concluded that evidence was insufficient to recommend routine PGx testing for depression treatment, highlighting methodological concerns and inconsistent effect sizes across trials.

Antipsychotic Pharmacogenomics

Evidence for PGx-guided antipsychotic prescribing is less robust than for antidepressants. CPIC provides dosing guidelines for CYP2D6-metabolized antipsychotics (aripiprazole, haloperidol, pimozide) and recommends dose reductions of 50–75% for aripiprazole in CYP2D6 PMs. However, no large RCT has demonstrated that PGx-guided antipsychotic selection improves clinical outcomes in schizophrenia or bipolar disorder. The pharmacogenomic landscape for antipsychotics is complicated by the fact that many second-generation antipsychotics have multiple metabolic pathways (e.g., quetiapine via CYP3A4), reducing the relative impact of any single gene variant.

Two major international consortia provide evidence-based pharmacogenomic dosing guidelines: the Clinical Pharmacogenetics Implementation Consortium (CPIC), based in the United States, and the Dutch Pharmacogenetics Working Group (DPWG), embedded in the Royal Dutch Association for the Advancement of Pharmacy. While their methodologies differ slightly, concordance between the two bodies is high for most recommendations.

Psychiatry-Relevant CPIC Guidelines (as of 2024)

• TCAs (amitriptyline, nortriptyline, clomipramine, desipramine, imipramine, trimiptyline): Level A guidelines for CYP2D6 and CYP2C19. CYP2D6 PMs: reduce dose by 50% with therapeutic drug monitoring (TDM). CYP2D6 UMs: increase dose by 25–50% or select alternative. CYP2C19 PMs (amitriptyline, imipramine): reduce dose by 50%.
• SSRIs (citalopram, escitalopram, sertraline, fluvoxamine, paroxetine): Level A for CYP2C19 (citalopram, escitalopram, sertraline). CYP2C19 UMs: consider alternative SSRI. CYP2C19 PMs: reduce citalopram to max 20 mg/day. Level A for CYP2D6 (paroxetine, fluvoxamine): PMs may have elevated levels; UMs may need dose increase or alternative.
• Venlafaxine/Desvenlafaxine: CYP2D6 PMs show increased venlafaxine:desvenlafaxine ratio. Desvenlafaxine preferred over venlafaxine in CYP2D6 PMs because it bypasses CYP2D6 metabolism.
• Atomoxetine: CYP2D6 PMs require 50% dose reduction. FDA label includes PGx information.
• Aripiprazole: CYP2D6 PMs should receive 50–67% of standard dose. Brexpiprazole: similar CYP2D6 recommendations.
• Carbamazepine/Oxcarbazepine: HLA-B*15:02 and HLA-A*31:01 testing recommended. Carriers should avoid carbamazepine due to SJS/TEN/DRESS risk.
• Clozapine: No CPIC guideline currently, though CYP1A2 phenotype significantly influences levels. Clinical practice emphasizes TDM (target trough level: 350–600 ng/mL).

CPIC guidelines assign levels of evidence: Level A indicates strong evidence with prescribing action recommended; Level B indicates moderate evidence with action recommended; and Level C indicates optional clinical action. Psychiatry-relevant drug-gene pairs at Level A include CYP2D6-TCAs, CYP2C19-SSRIs, CYP2D6-atomoxetine, and HLA-B*15:02-carbamazepine.

Allele frequency distributions for CYP450 enzymes vary dramatically across ancestral populations, creating both opportunities and challenges for equitable PGx implementation.

Key examples:

• CYP2D6*4 (nonfunctional): ~20–25% allele frequency in European populations, ~1–6% in East Asian and African populations.
• CYP2D6*10 (reduced function): ~40–50% allele frequency in East Asian populations, ~2–5% in European populations. This contributes to the substantially higher proportion of CYP2D6 IMs in East Asian populations.
• CYP2D6*17 (reduced function): ~20–35% allele frequency in sub-Saharan African populations, rare in European and East Asian populations.
• CYP2C19*2 (nonfunctional): ~12–23% in East Asian populations, ~12–15% in European populations, ~15–18% in African populations.
• CYP2C19*17 (ultrarapid): ~20–25% in European and Middle Eastern populations, ~2–4% in East Asian populations.

These differences mean that the probability of being a CYP2D6 PM is approximately 5–10% for European-ancestry patients but only 1–2% for East Asian patients, while the probability of being a CYP2D6 IM is higher in East Asian populations due to *10 prevalence. Clinically, this translates to different pretest probabilities of encountering actionable genotypes across populations, which is relevant for cost-effectiveness modeling.

A critical equity concern is that most GWAS and pharmacogenomic studies have been conducted in populations of predominantly European ancestry. The PharmGKB database estimates that >80% of pharmacogenomic research participants are of European descent. This creates an evidence gap for genetic variants more prevalent in African, Indigenous, Latin American, and South Asian populations, potentially leading to less accurate PGx-guided recommendations for these groups. Rare or novel CYP2D6 alleles in underrepresented populations may be miscalled as normal function by genotyping arrays that were designed based on European-ancestry variant catalogs.

The IGNITE (Implementing Genomics in Practice) network and the All of Us Research Program are working to address these disparities by enrolling diverse populations and cataloging population-specific allele frequencies.

As of 2024, several commercial PGx panels are marketed for psychiatric applications, including GeneSight (Myriad Genetics), Genomind PGx Express, Tempus Gene+, and OneOme RightMed. These panels typically assess 8–24 genes using buccal swab or saliva samples, with turnaround times of 3–7 business days.

Most panels use a combinatorial pharmacogenomic approach, integrating pharmacokinetic (CYP450) and pharmacodynamic gene results into a traffic-light or tiered classification system—often labeled "use as directed" (green), "moderate gene-drug interaction" (yellow), and "significant gene-drug interaction" (red). This combinatorial approach is proprietary and algorithm-dependent, meaning that different panels can yield discordant recommendations for the same patient.

A 2020 study by Bousman and Dunlop in Pharmacogenomics compared medication categorization across five commercial panels and found agreement for only ~50% of drug-gene pair classifications. This discordance arises from differences in which genes are included, how alleles are scored, and how combinatorial algorithms weight pharmacokinetic versus pharmacodynamic interactions. A patient could receive a "green" classification for a medication on one panel and a "yellow" on another, creating confusion for both patients and providers.

Clinicians should be aware that:

• Most commercial panels are genotyping arrays, not whole-gene sequencing. They detect known variants but may miss rare or novel alleles, structural variants, or complex rearrangements (particularly relevant for CYP2D6, which has a complex genomic locus with deletions, duplications, and hybrid genes).
• Panels do not account for phenoconversion—the process by which a genotypic normal metabolizer becomes a phenotypic poor metabolizer through concomitant use of a potent CYP inhibitor (e.g., fluoxetine or paroxetine inhibiting CYP2D6, or fluvoxamine inhibiting CYP1A2). A patient genotyped as a CYP2D6 NM who is prescribed fluoxetine plus a CYP2D6-metabolized medication may functionally behave as a PM.
• Therapeutic drug monitoring (TDM) remains the gold standard for real-time assessment of drug levels and should complement, not be replaced by, PGx testing. TDM integrates all sources of pharmacokinetic variability: genetics, drug interactions, hepatic function, renal function, age, body composition, and adherence.

Not all patients benefit equally from PGx-guided prescribing. Several clinical and genetic factors influence the yield and cost-effectiveness of testing:

Treatment-Resistant or Treatment-Intolerant Patients

The strongest clinical rationale for PGx testing exists in patients who have failed two or more adequate antidepressant or antipsychotic trials or who have experienced recurrent, unexplained adverse drug reactions. These patients have the highest pretest probability of harboring actionable pharmacogenomic variants. In the GUIDED trial, clinical benefit was most evident in the subgroup taking medications flagged as having significant gene-drug interactions at baseline—suggesting that PGx testing is most useful when it prompts a change from a pharmacogenomically "mismatched" medication.

Polypharmacy

Patients on multiple medications with overlapping CYP450 metabolism pathways are at higher risk of clinically significant gene-drug and drug-drug-gene interactions. A CYP2D6 IM taking both a CYP2D6-metabolized antidepressant and a CYP2D6 inhibitor may effectively become a PM—a phenomenon that PGx results can help anticipate. Psychiatric patients frequently take 3–6 concurrent psychotropic medications, making polypharmacy-related phenoconversion a realistic clinical scenario.

Extremes of Metabolizer Phenotype

PMs and UMs, who represent the phenotypic extremes, derive the most clear-cut dosing guidance from PGx testing. Approximately 7–10% of the general population are CYP2D6 PMs and 5–7% are CYP2D6 UMs across all ancestries combined, meaning that roughly 1 in 6–7 patients may have a clinically actionable CYP2D6 phenotype. For CYP2C19, the combined prevalence of PMs and UMs is similarly approximately 15–20%, varying substantially by ancestry.

Pediatric and Geriatric Populations

Children and older adults may be at disproportionate risk from pharmacogenomic extremes due to developmental or age-related changes in drug metabolism, body composition, and organ function. The FDA's black box warning on codeine in CYP2D6 UMs was prompted by pediatric deaths, highlighting the particular vulnerability of younger patients. In geriatric populations, the combination of reduced hepatic blood flow, polypharmacy, and a PM genotype may compound the risk of supratherapeutic drug levels and adverse events.

Factors That Limit Predictive Utility

PGx testing has reduced clinical utility when:

• The prescribed medication has multiple metabolic pathways (e.g., quetiapine via CYP3A4 with minor CYP2D6 involvement), reducing the impact of any single gene variant.
• The primary determinant of response is pharmacodynamic (receptor-level effects) rather than pharmacokinetic.
• Clinical factors such as nonadherence, substance use, hepatic impairment, or renal dysfunction dominate the variability in drug response.
• The medication has a wide therapeutic index (e.g., gabapentin, lithium with TDM), where moderate changes in drug level are unlikely to produce clinical consequences.

Despite growing enthusiasm, the evidence base for routine PGx implementation in psychiatry has significant limitations that clinicians must understand:

Methodological Concerns in RCTs

Most PGx RCTs in psychiatry have been open-label on the prescriber side—clinicians know whether they are in the PGx-guided arm, which may introduce bias through differential prescribing behavior (e.g., PGx-guided clinicians may be more attentive to medication selection, contributing to a Hawthorne-like effect). Truly double-blinded PGx trials are logistically difficult because the intervention is a recommendation, not a drug.

Combinatorial Algorithm Opacity

The proprietary algorithms used by commercial panels are not fully transparent. The weighting schemes for pharmacokinetic versus pharmacodynamic gene inputs, the handling of uncertain gene-function assignments, and the cut points for tier classification are often undisclosed. This limits independent replication and scientific scrutiny. A recommendation from a combinatorial panel is not equivalent to a CPIC guideline—the latter is based on transparent, peer-reviewed evidence with published strength-of-evidence ratings.

Limited Pharmacodynamic Evidence

While pharmacokinetic PGx (CYP450 metabolism) has strong mechanistic plausibility and quantifiable effects on drug levels, pharmacodynamic PGx in psychiatry remains largely investigational. Individual candidate gene variants (SLC6A4, HTR2A, COMT, DRD2) each explain only a small fraction of variance in treatment response—typically <2% individually. Psychiatric drug response is a complex polygenic trait, and genome-wide association studies (GWAS) have identified very few reproducible pharmacodynamic PGx signals. The International SSRI Pharmacogenomics Consortium (ISPC) has conducted large GWAS of antidepressant response and found that common variants collectively explain approximately 6–10% of variance in remission, with no single variant reaching genome-wide significance in a replicated manner.

Narrow Outcome Focus

Most PGx trials measure response and remission rates on depression rating scales (HAM-D, PHQ-9) over 8–12 weeks. Data on long-term outcomes (relapse prevention, quality of life, functional recovery, hospitalization rates, suicide risk) are sparse. A 2023 retrospective analysis of insurance claims data suggested PGx-tested patients had reduced healthcare utilization and lower rates of emergency department visits, but prospective confirmation is needed.

Cost-Effectiveness Uncertainty

PGx panel costs range from $300–$2,000 USD depending on the panel and payer status. Multiple health economic models have yielded conflicting conclusions. A 2022 cost-effectiveness analysis published in Pharmacogenomics estimated that PGx-guided antidepressant treatment was cost-effective at willingness-to-pay thresholds of $50,000 per quality-adjusted life year (QALY) gained, primarily by reducing the duration of inadequate treatment. However, these models are highly sensitive to assumptions about test sensitivity, clinician adherence to PGx recommendations, and baseline probability of encountering actionable results.

Several active research areas may substantially reshape psychiatric pharmacogenomics in the coming decade:

Polygenic Risk Scores for Treatment Response

Rather than single-gene analyses, polygenic scores (PGS) aggregate the effects of thousands of genetic variants identified through GWAS into a single composite risk estimate. PGS for antidepressant response are being developed through large consortium efforts, including the Psychiatric Genomics Consortium (PGC) Pharmacogenomics Working Group. Early results suggest modest but significant predictive ability beyond clinical variables alone, though clinical implementation remains premature.

Pharmacoepigenomics

Epigenetic modifications—DNA methylation, histone acetylation, and non-coding RNA expression—may mediate environmentally-induced changes in drug metabolism and target sensitivity. For example, childhood adversity has been associated with altered SLC6A4 methylation patterns, which may influence SSRI response independently of 5-HTTLPR genotype. This field is nascent but conceptually compelling.

Pharmacomicrobiomics

The gut microbiome expresses drug-metabolizing enzymes and can influence the bioavailability and metabolism of orally administered psychotropic medications. Emerging evidence suggests that gut microbial composition may influence circulating levels of certain antidepressants and mood-related metabolites (e.g., tryptophan-kynurenine pathway metabolites). The clinical relevance for PGx-guided prescribing is speculative but under active investigation.

Machine Learning Integration

Algorithmic approaches integrating pharmacogenomic data with electronic health record (EHR) data—including prior medication trials, comorbidities, lab values, and real-time drug interaction checking—represent a promising framework for clinical decision support. The eMERGE (Electronic Medical Records and Genomics) Network is piloting preemptive PGx testing integrated into EHR systems across multiple U.S. academic medical centers, with early data suggesting high rates of actionable PGx findings (~96–99% of patients carry at least one actionable PGx variant when a broad panel is tested).

Pharmacogenomics for Novel Therapeutics

As new psychiatric treatments enter clinical practice—including esketamine (CYP3A4/CYP2B6 metabolism), psilocybin (primarily MAO-A metabolism, CYP2D6 may play a minor role), and MDMA (CYP2D6-mediated)—pharmacogenomic characterization of these agents is an active research area. CYP2D6 polymorphisms may be particularly relevant for MDMA-assisted psychotherapy, as MDMA is extensively metabolized by CYP2D6, and PMs may be at increased risk of neurotoxicity and serotonin syndrome.

Given the current evidence, how should clinicians integrate PGx results into psychiatric practice? A pragmatic framework involves the following principles:

• Use PGx results as one input among many, not as a definitive prescribing algorithm. Clinical judgment, patient preference, treatment history, comorbidity profile, drug interaction risk, and cost all remain essential considerations.
• Prioritize CPIC Level A guidelines over proprietary combinatorial panel recommendations. When a CPIC or DPWG guideline provides a specific dosing recommendation for a drug-gene pair, that recommendation carries the strongest evidence base.
• Consider PGx testing preemptively or at the time of treatment failure/intolerance. Preemptive testing (before the first prescription) maximizes the lifetime utility of PGx data, as results are stable and apply across multiple medications and future prescribing decisions. The eMERGE Network has demonstrated the feasibility of this approach.
• Always account for phenoconversion. A genotypic NM taking a potent CYP inhibitor may functionally behave as a PM. PGx reports should be interpreted in the context of the patient's current medication list.
• Pair PGx testing with therapeutic drug monitoring when available. TDM provides real-time verification of predicted pharmacokinetic effects and captures non-genetic sources of variability.
• Document PGx results in the permanent medical record and communicate results to other prescribers. Pharmacogenomic results are lifelong; their value extends beyond the current prescribing encounter.

The American Psychiatric Association (APA) has not issued a formal practice guideline endorsing routine PGx testing but acknowledges its potential utility in treatment-resistant populations. The Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update includes PGx-guided prescribing as a recommended strategy for patients who have failed initial antidepressant treatment.

Pharmacogenomics in psychiatry has advanced from a theoretical concept to a clinical tool with a growing—but imperfect—evidence base. The strongest evidence supports CYP2D6- and CYP2C19-guided dosing of antidepressants (particularly TCAs and SSRIs) and HLA-B*15:02 screening before carbamazepine, with CPIC Level A guidelines providing specific, actionable recommendations. Emerging RCT data, including the IMPACT trial, suggest that combinatorial PGx-guided prescribing may improve depression remission rates with an NNT of approximately 6, though methodological limitations of existing trials warrant caution in extrapolating these results broadly.

The field's most significant limitations include the opacity of commercial combinatorial algorithms, the gap in evidence for antipsychotic and mood stabilizer PGx, the predominance of European-ancestry research cohorts, and the relatively small proportion of treatment response variance explained by currently testable genes. Pharmacogenomics does not resolve the fundamental complexity of psychiatric treatment response, which is shaped by neurobiological heterogeneity within diagnostic categories, psychosocial determinants, and placebo effects.

For clinicians, the most evidence-based approach is to use PGx testing as a complementary tool—particularly for treatment-resistant or treatment-intolerant patients—integrated with clinical expertise, therapeutic drug monitoring, and shared decision-making. As polygenic approaches mature, diverse populations are better represented in research, and machine-learning-enhanced clinical decision support systems are validated, pharmacogenomics is poised to become an increasingly valuable—though never sufficient—component of psychiatric precision medicine.